pharma · Refractory Focal Onset Epilepsy · Early Parkinson’s Disease
Biohaven Bioscience Ireland
Biohaven Bioscience Ireland Limited
Biohaven Bioscience Ireland clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- GB
- Programs
- 7
- Drugs
- 8
- Patents
- 0
Biohaven Bioscience Ireland projects
7 ClinicalTrials.gov programs sponsored by Biohaven Bioscience Ireland.
Biohaven Bioscience Ireland has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BHV7000-303
Biohaven Bioscience Ireland Limited
Refractory Focal Onset Epilepsy
1 trial -
BHV7000-304
Biohaven Bioscience Ireland Limited
Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures
1 trial -
BHV8000-301
Biohaven Bioscience Ireland Limited
Early Parkinson’s Disease
1 trial -
BHV-7000, BHV-7000
Biohaven Bioscience Ireland Limited
Refractory Focal Onset Epilepsy
1 trial -
BHV7000-302
Biohaven Bioscience Ireland Limited
Refractory Focal Onset Epilepsy
1 trial -
BHV-1300
Biohaven Bioscience Ireland Limited
Graves Disease
1 trial -
BHV2100-112
Biohaven Bioscience Ireland Limited
Pain
1 trial
Frequently asked questions
How many clinical projects does Biohaven Bioscience Ireland have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.